| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 93 | 2026 | 2377 | 7.910 |
Why?
|
| Outpatients | 17 | 2025 | 447 | 4.870 |
Why?
|
| Critical Illness | 28 | 2026 | 899 | 4.670 |
Why?
|
| Hospitalization | 64 | 2026 | 2458 | 4.010 |
Why?
|
| Sepsis | 21 | 2024 | 662 | 3.820 |
Why?
|
| Intubation, Intratracheal | 24 | 2026 | 325 | 3.770 |
Why?
|
| Vitamin D | 22 | 2025 | 403 | 3.210 |
Why?
|
| Vitamin D Deficiency | 14 | 2021 | 190 | 2.640 |
Why?
|
| Wounds and Injuries | 12 | 2026 | 960 | 2.480 |
Why?
|
| Influenza, Human | 17 | 2026 | 624 | 2.330 |
Why?
|
| Adult | 177 | 2026 | 40665 | 2.320 |
Why?
|
| Hyperoxia | 5 | 2026 | 96 | 2.280 |
Why?
|
| Humans | 316 | 2026 | 145140 | 2.260 |
Why?
|
| Aged | 132 | 2026 | 26096 | 2.260 |
Why?
|
| Oxygen | 15 | 2026 | 978 | 2.260 |
Why?
|
| Emergency Medicine | 14 | 2025 | 282 | 2.230 |
Why?
|
| Antiviral Agents | 11 | 2026 | 767 | 2.190 |
Why?
|
| Cholecalciferol | 7 | 2024 | 61 | 2.130 |
Why?
|
| Middle Aged | 157 | 2026 | 36126 | 2.120 |
Why?
|
| Hospital Mortality | 23 | 2025 | 1038 | 2.080 |
Why?
|
| Emergency Medical Services | 15 | 2025 | 684 | 2.050 |
Why?
|
| Antibodies, Monoclonal | 12 | 2025 | 1505 | 2.020 |
Why?
|
| United States | 105 | 2026 | 16065 | 1.990 |
Why?
|
| Antibodies, Neutralizing | 10 | 2025 | 340 | 1.990 |
Why?
|
| Influenza Vaccines | 15 | 2026 | 534 | 1.980 |
Why?
|
| Physician Assistants | 7 | 2014 | 101 | 1.980 |
Why?
|
| Laryngoscopy | 10 | 2025 | 119 | 1.950 |
Why?
|
| Patient Discharge | 11 | 2022 | 991 | 1.950 |
Why?
|
| Length of Stay | 22 | 2026 | 1348 | 1.920 |
Why?
|
| Respiration, Artificial | 12 | 2026 | 713 | 1.830 |
Why?
|
| Laryngoscopes | 9 | 2025 | 45 | 1.740 |
Why?
|
| Male | 183 | 2026 | 72664 | 1.740 |
Why?
|
| Oxygen Inhalation Therapy | 7 | 2026 | 181 | 1.670 |
Why?
|
| Ritonavir | 3 | 2023 | 75 | 1.650 |
Why?
|
| Respiratory Tract Infections | 8 | 2025 | 394 | 1.630 |
Why?
|
| Female | 179 | 2026 | 78636 | 1.590 |
Why?
|
| Hospitals | 9 | 2023 | 732 | 1.570 |
Why?
|
| Intensive Care Units | 12 | 2026 | 924 | 1.510 |
Why?
|
| Adenosine Monophosphate | 7 | 2026 | 85 | 1.500 |
Why?
|
| Patient Transfer | 5 | 2015 | 211 | 1.450 |
Why?
|
| Alanine | 6 | 2025 | 168 | 1.410 |
Why?
|
| Wound Infection | 3 | 2026 | 59 | 1.330 |
Why?
|
| Antibodies, Viral | 8 | 2025 | 673 | 1.280 |
Why?
|
| Patient Readmission | 5 | 2022 | 769 | 1.280 |
Why?
|
| Health Services Accessibility | 11 | 2019 | 1099 | 1.260 |
Why?
|
| Vitamins | 8 | 2025 | 182 | 1.240 |
Why?
|
| Cross-Sectional Studies | 35 | 2025 | 5886 | 1.200 |
Why?
|
| Retrospective Studies | 47 | 2026 | 17247 | 1.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 6 | 2026 | 139 | 1.170 |
Why?
|
| Aged, 80 and over | 37 | 2025 | 8318 | 1.150 |
Why?
|
| Health Care Rationing | 2 | 2024 | 56 | 1.140 |
Why?
|
| Adolescent | 67 | 2026 | 22479 | 1.140 |
Why?
|
| Patient Admission | 7 | 2017 | 220 | 1.110 |
Why?
|
| Nursing Homes | 3 | 2015 | 173 | 1.090 |
Why?
|
| Vaccination | 23 | 2026 | 1423 | 1.070 |
Why?
|
| Young Adult | 49 | 2026 | 14176 | 1.030 |
Why?
|
| Clinical Trials as Topic | 5 | 2026 | 1058 | 1.010 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 2 | 2026 | 33 | 1.010 |
Why?
|
| Androstanols | 2 | 2026 | 30 | 1.010 |
Why?
|
| Rural Health Services | 8 | 2020 | 138 | 1.010 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2023 | 453 | 1.000 |
Why?
|
| Hydroxychloroquine | 3 | 2022 | 65 | 0.990 |
Why?
|
| Health Care Surveys | 17 | 2020 | 535 | 0.990 |
Why?
|
| Physicians | 10 | 2023 | 954 | 0.980 |
Why?
|
| Treatment Outcome | 36 | 2026 | 11741 | 0.980 |
Why?
|
| Medicaid | 4 | 2015 | 466 | 0.970 |
Why?
|
| Referral and Consultation | 7 | 2026 | 862 | 0.970 |
Why?
|
| Pneumonia | 5 | 2021 | 635 | 0.950 |
Why?
|
| Airway Management | 3 | 2024 | 81 | 0.950 |
Why?
|
| Diabetes Mellitus | 7 | 2024 | 1092 | 0.920 |
Why?
|
| Nurse Practitioners | 4 | 2012 | 138 | 0.900 |
Why?
|
| Rehabilitation Centers | 2 | 2015 | 39 | 0.890 |
Why?
|
| Stroke | 6 | 2025 | 1270 | 0.880 |
Why?
|
| Mass Screening | 7 | 2012 | 1354 | 0.850 |
Why?
|
| Pneumonia, Viral | 7 | 2026 | 388 | 0.830 |
Why?
|
| Hypoxia | 9 | 2026 | 1197 | 0.830 |
Why?
|
| Coronavirus Infections | 7 | 2026 | 382 | 0.830 |
Why?
|
| Warfare | 2 | 2026 | 98 | 0.800 |
Why?
|
| Insurance, Health | 5 | 2020 | 310 | 0.800 |
Why?
|
| Shock, Traumatic | 1 | 2023 | 14 | 0.770 |
Why?
|
| Medically Uninsured | 3 | 2014 | 132 | 0.770 |
Why?
|
| Asthma | 11 | 2012 | 1795 | 0.740 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2026 | 1742 | 0.740 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2022 | 17 | 0.720 |
Why?
|
| Military Personnel | 4 | 2023 | 736 | 0.710 |
Why?
|
| Minority Groups | 2 | 2023 | 284 | 0.700 |
Why?
|
| Health Services Needs and Demand | 3 | 2013 | 279 | 0.700 |
Why?
|
| Brain Ischemia | 4 | 2025 | 359 | 0.700 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 66 | 0.690 |
Why?
|
| Double-Blind Method | 19 | 2026 | 2057 | 0.680 |
Why?
|
| Prospective Studies | 25 | 2025 | 8035 | 0.670 |
Why?
|
| Primary Health Care | 6 | 2019 | 1725 | 0.660 |
Why?
|
| Surgical Procedures, Operative | 3 | 2025 | 271 | 0.660 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 3 | 2025 | 39 | 0.660 |
Why?
|
| Multicenter Studies as Topic | 10 | 2026 | 410 | 0.660 |
Why?
|
| Internship and Residency | 8 | 2023 | 1264 | 0.650 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 130 | 0.650 |
Why?
|
| Pandemics | 12 | 2026 | 1703 | 0.630 |
Why?
|
| Age Factors | 13 | 2025 | 3338 | 0.630 |
Why?
|
| Severity of Illness Index | 14 | 2026 | 2928 | 0.620 |
Why?
|
| Career Choice | 3 | 2010 | 234 | 0.620 |
Why?
|
| Acute Kidney Injury | 6 | 2025 | 872 | 0.610 |
Why?
|
| Resuscitation Orders | 2 | 2019 | 48 | 0.610 |
Why?
|
| Substance Abuse Detection | 1 | 2021 | 106 | 0.600 |
Why?
|
| Tracheostomy | 1 | 2021 | 142 | 0.600 |
Why?
|
| Cohort Studies | 18 | 2025 | 5988 | 0.580 |
Why?
|
| Personnel Selection | 2 | 2010 | 91 | 0.580 |
Why?
|
| Spine | 1 | 2021 | 181 | 0.580 |
Why?
|
| Dietary Supplements | 8 | 2025 | 582 | 0.580 |
Why?
|
| Translating | 2 | 2010 | 50 | 0.580 |
Why?
|
| Point-of-Care Systems | 4 | 2025 | 188 | 0.560 |
Why?
|
| Critical Care | 5 | 2022 | 702 | 0.560 |
Why?
|
| Machine Learning | 1 | 2024 | 586 | 0.560 |
Why?
|
| Electronic Health Records | 6 | 2026 | 1188 | 0.560 |
Why?
|
| Triage | 3 | 2020 | 250 | 0.550 |
Why?
|
| Resuscitation | 1 | 2021 | 310 | 0.550 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2025 | 159 | 0.540 |
Why?
|
| Conservative Treatment | 1 | 2018 | 44 | 0.540 |
Why?
|
| Acute Disease | 11 | 2025 | 1035 | 0.540 |
Why?
|
| Sex Factors | 11 | 2026 | 2099 | 0.530 |
Why?
|
| Anxiety | 1 | 2025 | 1117 | 0.520 |
Why?
|
| Communication Barriers | 2 | 2010 | 130 | 0.520 |
Why?
|
| Brain Injuries | 1 | 2023 | 507 | 0.520 |
Why?
|
| Health Surveys | 4 | 2014 | 517 | 0.520 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 50 | 0.510 |
Why?
|
| Guideline Adherence | 6 | 2022 | 586 | 0.500 |
Why?
|
| Interdisciplinary Studies | 1 | 2016 | 30 | 0.490 |
Why?
|
| Professional Autonomy | 2 | 2014 | 29 | 0.490 |
Why?
|
| Financing, Organized | 1 | 2016 | 36 | 0.490 |
Why?
|
| MicroRNAs | 3 | 2017 | 686 | 0.480 |
Why?
|
| Colorado | 11 | 2025 | 4538 | 0.480 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 232 | 0.480 |
Why?
|
| Obesity | 4 | 2022 | 3097 | 0.480 |
Why?
|
| Skilled Nursing Facilities | 2 | 2016 | 152 | 0.470 |
Why?
|
| Language | 2 | 2010 | 322 | 0.470 |
Why?
|
| Surveys and Questionnaires | 11 | 2025 | 6055 | 0.470 |
Why?
|
| Orthopedics | 1 | 2018 | 170 | 0.460 |
Why?
|
| Databases, Factual | 10 | 2021 | 1488 | 0.460 |
Why?
|
| Noninvasive Ventilation | 3 | 2025 | 62 | 0.460 |
Why?
|
| Oxazines | 2 | 2026 | 37 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 992 | 0.460 |
Why?
|
| Home Care Services | 2 | 2016 | 282 | 0.460 |
Why?
|
| Boston | 8 | 2010 | 93 | 0.450 |
Why?
|
| Risk Factors | 17 | 2026 | 10857 | 0.440 |
Why?
|
| Case-Control Studies | 16 | 2026 | 3616 | 0.440 |
Why?
|
| Communication | 2 | 2014 | 973 | 0.440 |
Why?
|
| Emergencies | 3 | 2015 | 174 | 0.440 |
Why?
|
| Insurance Coverage | 3 | 2016 | 244 | 0.440 |
Why?
|
| Multiple Trauma | 1 | 2016 | 121 | 0.430 |
Why?
|
| Homes for the Aged | 1 | 2015 | 32 | 0.430 |
Why?
|
| Healthcare Disparities | 3 | 2012 | 731 | 0.430 |
Why?
|
| Calcitriol | 3 | 2025 | 57 | 0.430 |
Why?
|
| Cross Infection | 2 | 2020 | 260 | 0.430 |
Why?
|
| Halfway Houses | 1 | 2014 | 2 | 0.430 |
Why?
|
| Hyperglycemia | 2 | 2009 | 379 | 0.420 |
Why?
|
| Catheterization, Central Venous | 1 | 2016 | 123 | 0.420 |
Why?
|
| Pilot Projects | 7 | 2023 | 1889 | 0.420 |
Why?
|
| Acute Lung Injury | 3 | 2025 | 305 | 0.420 |
Why?
|
| Shock, Septic | 4 | 2018 | 227 | 0.410 |
Why?
|
| Organ Dysfunction Scores | 3 | 2024 | 55 | 0.400 |
Why?
|
| Oximetry | 3 | 2026 | 125 | 0.400 |
Why?
|
| Nutrition Surveys | 6 | 2011 | 279 | 0.400 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 95 | 0.400 |
Why?
|
| Patient Compliance | 3 | 2008 | 587 | 0.400 |
Why?
|
| Renin-Angiotensin System | 2 | 2025 | 80 | 0.400 |
Why?
|
| Faculty, Medical | 1 | 2016 | 301 | 0.390 |
Why?
|
| Betacoronavirus | 3 | 2020 | 287 | 0.390 |
Why?
|
| Urban Health Services | 5 | 2020 | 68 | 0.390 |
Why?
|
| Biomarkers | 13 | 2026 | 4282 | 0.390 |
Why?
|
| Hospitals, Rural | 2 | 2010 | 49 | 0.380 |
Why?
|
| Research Design | 5 | 2026 | 1132 | 0.380 |
Why?
|
| Hypoglycemia | 2 | 2008 | 479 | 0.380 |
Why?
|
| Time Factors | 16 | 2025 | 7107 | 0.380 |
Why?
|
| International Educational Exchange | 1 | 2012 | 10 | 0.370 |
Why?
|
| Lung Injury | 2 | 2026 | 241 | 0.370 |
Why?
|
| Logistic Models | 8 | 2024 | 2133 | 0.370 |
Why?
|
| California | 5 | 2019 | 471 | 0.370 |
Why?
|
| Positive-Pressure Respiration | 3 | 2025 | 115 | 0.370 |
Why?
|
| Interleukin-6 | 3 | 2026 | 775 | 0.370 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 600 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2025 | 1415 | 0.360 |
Why?
|
| Odds Ratio | 6 | 2018 | 1082 | 0.360 |
Why?
|
| International Classification of Diseases | 2 | 2014 | 149 | 0.360 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 364 | 0.360 |
Why?
|
| Health Resources | 1 | 2013 | 130 | 0.360 |
Why?
|
| Renal Dialysis | 1 | 2016 | 466 | 0.360 |
Why?
|
| Treatment Failure | 6 | 2022 | 360 | 0.360 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1145 | 0.360 |
Why?
|
| Medicare | 3 | 2015 | 902 | 0.360 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 1546 | 0.350 |
Why?
|
| Observation | 1 | 2011 | 54 | 0.350 |
Why?
|
| Hospital Units | 1 | 2011 | 32 | 0.340 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 506 | 0.340 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2011 | 12 | 0.340 |
Why?
|
| Patient Education as Topic | 4 | 2010 | 775 | 0.340 |
Why?
|
| Liability, Legal | 1 | 2011 | 42 | 0.340 |
Why?
|
| Malpractice | 1 | 2011 | 44 | 0.340 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 96 | 0.330 |
Why?
|
| Respiratory Insufficiency | 2 | 2026 | 326 | 0.330 |
Why?
|
| Pyridines | 2 | 2026 | 608 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2767 | 0.330 |
Why?
|
| Adaptive Clinical Trials as Topic | 4 | 2024 | 24 | 0.330 |
Why?
|
| Patient Safety | 2 | 2016 | 355 | 0.320 |
Why?
|
| Influenza B virus | 3 | 2025 | 47 | 0.320 |
Why?
|
| Training Support | 1 | 2010 | 35 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2026 | 2026 | 0.320 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 114 | 0.320 |
Why?
|
| Risk Assessment | 9 | 2025 | 3740 | 0.320 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 30 | 0.320 |
Why?
|
| Ambulatory Care | 5 | 2023 | 608 | 0.320 |
Why?
|
| Inpatients | 2 | 2021 | 552 | 0.320 |
Why?
|
| South Africa | 4 | 2025 | 266 | 0.320 |
Why?
|
| Military Medicine | 2 | 2022 | 148 | 0.320 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 10 | 0.310 |
Why?
|
| Occult Blood | 1 | 2010 | 40 | 0.310 |
Why?
|
| Blood Glucose | 3 | 2008 | 2335 | 0.300 |
Why?
|
| Ambulances | 3 | 2023 | 52 | 0.300 |
Why?
|
| Ukraine | 2 | 2026 | 36 | 0.300 |
Why?
|
| Patient Care | 1 | 2010 | 119 | 0.300 |
Why?
|
| Child | 22 | 2024 | 22670 | 0.290 |
Why?
|
| Inflammation | 1 | 2021 | 2876 | 0.290 |
Why?
|
| Intrauterine Devices | 1 | 2009 | 29 | 0.290 |
Why?
|
| Seasons | 7 | 2025 | 538 | 0.290 |
Why?
|
| Urban Population | 4 | 2025 | 492 | 0.290 |
Why?
|
| Bias | 3 | 2024 | 197 | 0.280 |
Why?
|
| Clinical Competence | 4 | 2025 | 1240 | 0.280 |
Why?
|
| Cause of Death | 2 | 2017 | 470 | 0.270 |
Why?
|
| Atracurium | 2 | 2019 | 14 | 0.270 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 1321 | 0.270 |
Why?
|
| Masks | 2 | 2025 | 70 | 0.270 |
Why?
|
| Neuromuscular Blocking Agents | 2 | 2019 | 28 | 0.270 |
Why?
|
| Mathematics | 1 | 2008 | 101 | 0.270 |
Why?
|
| Body Mass Index | 4 | 2019 | 2437 | 0.260 |
Why?
|
| Morpholines | 2 | 2026 | 130 | 0.260 |
Why?
|
| Prevalence | 7 | 2026 | 2855 | 0.260 |
Why?
|
| Immunization, Passive | 2 | 2025 | 90 | 0.260 |
Why?
|
| Video Recording | 6 | 2025 | 217 | 0.250 |
Why?
|
| Age Distribution | 4 | 2014 | 402 | 0.250 |
Why?
|
| Medical Futility | 2 | 2024 | 32 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 919 | 0.250 |
Why?
|
| Influenza A virus | 2 | 2025 | 116 | 0.250 |
Why?
|
| Registries | 4 | 2024 | 2401 | 0.240 |
Why?
|
| Immunization | 2 | 2025 | 375 | 0.240 |
Why?
|
| Heart Arrest | 3 | 2025 | 408 | 0.240 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4552 | 0.240 |
Why?
|
| Informed Consent | 2 | 2026 | 198 | 0.240 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2026 | 81 | 0.240 |
Why?
|
| Data Collection | 4 | 2014 | 639 | 0.240 |
Why?
|
| Ivermectin | 2 | 2023 | 14 | 0.240 |
Why?
|
| Crush Injuries | 1 | 2025 | 14 | 0.230 |
Why?
|
| Disease Progression | 6 | 2026 | 2857 | 0.230 |
Why?
|
| Etomidate | 1 | 2025 | 21 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 3892 | 0.230 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2026 | 132 | 0.230 |
Why?
|
| War-Related Injuries | 1 | 2026 | 46 | 0.230 |
Why?
|
| Emergency Treatment | 3 | 2019 | 123 | 0.230 |
Why?
|
| Disclosure | 1 | 2026 | 84 | 0.230 |
Why?
|
| Calcifediol | 1 | 2025 | 31 | 0.230 |
Why?
|
| Prochlorperazine | 1 | 2025 | 10 | 0.230 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 177 | 0.230 |
Why?
|
| Oseltamivir | 1 | 2025 | 17 | 0.230 |
Why?
|
| Multimorbidity | 1 | 2026 | 64 | 0.220 |
Why?
|
| Vasoconstrictor Agents | 3 | 2024 | 150 | 0.220 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2021 | 271 | 0.220 |
Why?
|
| Renin | 1 | 2024 | 33 | 0.220 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 35 | 0.220 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 390 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 6 | 2026 | 1922 | 0.220 |
Why?
|
| Bayes Theorem | 2 | 2026 | 419 | 0.210 |
Why?
|
| Vaccines, Synthetic | 5 | 2022 | 137 | 0.210 |
Why?
|
| Hospitals, Urban | 3 | 2016 | 142 | 0.210 |
Why?
|
| Cyclopropanes | 1 | 2024 | 84 | 0.210 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2024 | 103 | 0.210 |
Why?
|
| Glycocalyx | 1 | 2024 | 30 | 0.210 |
Why?
|
| Acetates | 1 | 2024 | 78 | 0.210 |
Why?
|
| Ketamine | 1 | 2025 | 137 | 0.210 |
Why?
|
| Medical Audit | 2 | 2018 | 77 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 465 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.210 |
Why?
|
| Glycine | 1 | 2025 | 186 | 0.210 |
Why?
|
| Choice Behavior | 2 | 2019 | 179 | 0.210 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 600 | 0.200 |
Why?
|
| Fluid Therapy | 2 | 2023 | 154 | 0.200 |
Why?
|
| Altitude Sickness | 1 | 2025 | 141 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2022 | 1806 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2026 | 222 | 0.200 |
Why?
|
| Incidence | 4 | 2025 | 2915 | 0.200 |
Why?
|
| Sulfides | 1 | 2024 | 92 | 0.200 |
Why?
|
| Multiple Organ Failure | 1 | 2024 | 120 | 0.200 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 587 | 0.200 |
Why?
|
| Hypotension | 2 | 2023 | 127 | 0.200 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2006 | 209 | 0.200 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 207 | 0.200 |
Why?
|
| Androstadienes | 1 | 2023 | 75 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 269 | 0.200 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 25 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 202 | 0.190 |
Why?
|
| Lactams | 1 | 2023 | 28 | 0.190 |
Why?
|
| Quinolines | 1 | 2024 | 190 | 0.190 |
Why?
|
| Electronics | 1 | 2023 | 65 | 0.190 |
Why?
|
| Child, Preschool | 12 | 2019 | 11835 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 296 | 0.190 |
Why?
|
| Comorbidity | 4 | 2021 | 1657 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 127 | 0.190 |
Why?
|
| Lopinavir | 1 | 2022 | 30 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 881 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2023 | 2803 | 0.190 |
Why?
|
| Plasma | 1 | 2024 | 223 | 0.180 |
Why?
|
| Proline | 1 | 2023 | 82 | 0.180 |
Why?
|
| Leucine | 1 | 2023 | 116 | 0.180 |
Why?
|
| Health Services Research | 2 | 2016 | 391 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 1186 | 0.180 |
Why?
|
| Equivalence Trials as Topic | 1 | 2022 | 35 | 0.180 |
Why?
|
| Violence | 1 | 2025 | 278 | 0.180 |
Why?
|
| Cytokines | 2 | 2014 | 2048 | 0.180 |
Why?
|
| Recovery of Function | 3 | 2022 | 715 | 0.180 |
Why?
|
| Delirium | 1 | 2023 | 105 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 3 | 2025 | 58 | 0.180 |
Why?
|
| Syncope | 1 | 2022 | 56 | 0.180 |
Why?
|
| Blood Transfusion | 1 | 2025 | 407 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2004 | 210 | 0.180 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2024 | 154 | 0.170 |
Why?
|
| Nitriles | 1 | 2023 | 207 | 0.170 |
Why?
|
| Metformin | 1 | 2025 | 327 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 92 | 0.170 |
Why?
|
| Veterans Health | 1 | 2023 | 189 | 0.170 |
Why?
|
| Acetaminophen | 1 | 2024 | 266 | 0.170 |
Why?
|
| Mountaineering | 2 | 2025 | 36 | 0.170 |
Why?
|
| Immunization Programs | 1 | 2023 | 193 | 0.170 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 13 | 0.170 |
Why?
|
| Malawi | 1 | 2021 | 57 | 0.170 |
Why?
|
| Polypharmacy | 1 | 2022 | 94 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2025 | 336 | 0.170 |
Why?
|
| Wounds, Penetrating | 1 | 2022 | 72 | 0.170 |
Why?
|
| Vasodilator Agents | 1 | 2023 | 330 | 0.170 |
Why?
|
| Health Policy | 1 | 2024 | 400 | 0.170 |
Why?
|
| Sentinel Surveillance | 3 | 2025 | 46 | 0.170 |
Why?
|
| Abdominal Pain | 1 | 2022 | 149 | 0.170 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 287 | 0.160 |
Why?
|
| Work | 1 | 2020 | 23 | 0.160 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 552 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2012 | 92 | 0.160 |
Why?
|
| Quality of Health Care | 3 | 2010 | 692 | 0.160 |
Why?
|
| Telecommunications | 1 | 2020 | 19 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2020 | 26 | 0.160 |
Why?
|
| Aftercare | 1 | 2022 | 222 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 328 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 3 | 2026 | 368 | 0.160 |
Why?
|
| Herpes Zoster | 1 | 2024 | 318 | 0.160 |
Why?
|
| Burns | 1 | 2025 | 374 | 0.160 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 527 | 0.160 |
Why?
|
| Rural Population | 3 | 2016 | 657 | 0.150 |
Why?
|
| Abbreviated Injury Scale | 1 | 2019 | 28 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2025 | 822 | 0.150 |
Why?
|
| Personnel Turnover | 2 | 2010 | 40 | 0.150 |
Why?
|
| Neuromuscular Blockade | 2 | 2019 | 53 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2025 | 1995 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2003 | 664 | 0.150 |
Why?
|
| Iraq | 1 | 2019 | 66 | 0.150 |
Why?
|
| Pulmonary Embolism | 2 | 2025 | 241 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 80 | 0.150 |
Why?
|
| Agkistrodon | 1 | 2019 | 6 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 483 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2024 | 1002 | 0.150 |
Why?
|
| Afghanistan | 1 | 2019 | 96 | 0.150 |
Why?
|
| Physical Therapy Modalities | 1 | 2023 | 335 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 1393 | 0.150 |
Why?
|
| Antivenins | 1 | 2019 | 29 | 0.150 |
Why?
|
| Snake Bites | 1 | 2019 | 24 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2020 | 136 | 0.150 |
Why?
|
| Infant | 7 | 2019 | 10060 | 0.150 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 56 | 0.150 |
Why?
|
| Crotalid Venoms | 1 | 2019 | 30 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2022 | 250 | 0.150 |
Why?
|
| Continuity of Patient Care | 2 | 2012 | 296 | 0.150 |
Why?
|
| Dantrolene | 1 | 2019 | 5 | 0.150 |
Why?
|
| Lactic Acid | 1 | 2020 | 292 | 0.150 |
Why?
|
| Consensus | 1 | 2021 | 478 | 0.150 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2019 | 6 | 0.150 |
Why?
|
| Malignant Hyperthermia | 1 | 2019 | 8 | 0.140 |
Why?
|
| Succinylcholine | 1 | 2019 | 7 | 0.140 |
Why?
|
| Muscle Relaxants, Central | 1 | 2019 | 14 | 0.140 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 171 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 336 | 0.140 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 193 | 0.140 |
Why?
|
| Injury Severity Score | 2 | 2022 | 599 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2025 | 2961 | 0.140 |
Why?
|
| Platelet-Rich Plasma | 1 | 2018 | 41 | 0.140 |
Why?
|
| Formative Feedback | 1 | 2018 | 35 | 0.140 |
Why?
|
| Renal Replacement Therapy | 3 | 2025 | 100 | 0.140 |
Why?
|
| Needs Assessment | 3 | 2010 | 401 | 0.130 |
Why?
|
| Vaccines | 1 | 2023 | 388 | 0.130 |
Why?
|
| Hospitals, Teaching | 2 | 2011 | 120 | 0.130 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 103 | 0.130 |
Why?
|
| ROC Curve | 3 | 2025 | 617 | 0.130 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 121 | 0.130 |
Why?
|
| Survivors | 1 | 2021 | 522 | 0.130 |
Why?
|
| Maryland | 1 | 2017 | 67 | 0.130 |
Why?
|
| Neutrophils | 2 | 2026 | 1123 | 0.130 |
Why?
|
| Income | 2 | 2008 | 201 | 0.130 |
Why?
|
| Civil Defense | 1 | 2017 | 20 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2018 | 182 | 0.120 |
Why?
|
| Time-to-Treatment | 4 | 2021 | 250 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 2183 | 0.120 |
Why?
|
| Infusions, Intravenous | 3 | 2024 | 428 | 0.120 |
Why?
|
| Assisted Living Facilities | 1 | 2016 | 20 | 0.120 |
Why?
|
| Certification | 3 | 2020 | 119 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 188 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 718 | 0.120 |
Why?
|
| Avalanches | 1 | 2016 | 2 | 0.120 |
Why?
|
| Trachea | 3 | 2023 | 258 | 0.120 |
Why?
|
| Cognition | 2 | 2023 | 1262 | 0.120 |
Why?
|
| Executive Function | 1 | 2021 | 469 | 0.120 |
Why?
|
| Educational Status | 2 | 2008 | 465 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 243 | 0.120 |
Why?
|
| Accidental Falls | 2 | 2016 | 225 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2020 | 577 | 0.120 |
Why?
|
| AIDS Serodiagnosis | 2 | 2012 | 23 | 0.110 |
Why?
|
| Advance Directives | 1 | 2016 | 88 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2017 | 148 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 890 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 739 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 141 | 0.110 |
Why?
|
| Self Report | 3 | 2025 | 867 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2115 | 0.110 |
Why?
|
| RNA, Viral | 3 | 2024 | 690 | 0.110 |
Why?
|
| Aminopyridines | 2 | 2026 | 129 | 0.110 |
Why?
|
| Awareness | 1 | 2015 | 110 | 0.110 |
Why?
|
| Angiotensin I | 2 | 2025 | 7 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2018 | 459 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 640 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2015 | 136 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 1325 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2014 | 6435 | 0.100 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 23 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 250 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2010 | 330 | 0.100 |
Why?
|
| Creatinine | 1 | 2015 | 513 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 858 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2017 | 425 | 0.100 |
Why?
|
| Fluvoxamine | 2 | 2023 | 17 | 0.100 |
Why?
|
| Risk | 2 | 2017 | 916 | 0.100 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 547 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2025 | 1109 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2016 | 231 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 946 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2017 | 258 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 113 | 0.100 |
Why?
|
| Anesthesiology | 1 | 2016 | 178 | 0.090 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 49 | 0.090 |
Why?
|
| Physician's Role | 1 | 2014 | 222 | 0.090 |
Why?
|
| Headache | 1 | 2013 | 151 | 0.090 |
Why?
|
| Immunization Schedule | 2 | 2025 | 186 | 0.090 |
Why?
|
| Quality of Life | 2 | 2025 | 3194 | 0.090 |
Why?
|
| Preventive Health Services | 2 | 2012 | 153 | 0.090 |
Why?
|
| Neoplasms | 1 | 2008 | 2900 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2021 | 1293 | 0.090 |
Why?
|
| Antigens, Viral | 2 | 2024 | 182 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2013 | 125 | 0.090 |
Why?
|
| Trauma Centers | 2 | 2025 | 465 | 0.090 |
Why?
|
| Immune System | 1 | 2013 | 177 | 0.090 |
Why?
|
| Sampling Studies | 1 | 2012 | 98 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1264 | 0.090 |
Why?
|
| Oregon | 1 | 2011 | 76 | 0.090 |
Why?
|
| Georgia | 1 | 2011 | 79 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2026 | 530 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2013 | 386 | 0.090 |
Why?
|
| Massachusetts | 1 | 2011 | 180 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2016 | 426 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 781 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2017 | 1127 | 0.080 |
Why?
|
| HIV | 1 | 2012 | 251 | 0.080 |
Why?
|
| Prognosis | 3 | 2026 | 4310 | 0.080 |
Why?
|
| Professional Practice Location | 1 | 2010 | 26 | 0.080 |
Why?
|
| Specialization | 1 | 2011 | 135 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 427 | 0.080 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2011 | 103 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2011 | 109 | 0.080 |
Why?
|
| Legislation as Topic | 1 | 2010 | 5 | 0.080 |
Why?
|
| Delegation, Professional | 1 | 2010 | 1 | 0.080 |
Why?
|
| Viral Load | 2 | 2023 | 525 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 80 | 0.080 |
Why?
|
| Emergency Nursing | 1 | 2010 | 22 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2025 | 693 | 0.080 |
Why?
|
| Occupations | 1 | 2010 | 50 | 0.080 |
Why?
|
| Albuterol | 1 | 2010 | 76 | 0.080 |
Why?
|
| Medically Underserved Area | 1 | 2010 | 100 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3114 | 0.080 |
Why?
|
| Allied Health Personnel | 1 | 2010 | 53 | 0.080 |
Why?
|
| Medical Order Entry Systems | 1 | 2010 | 40 | 0.080 |
Why?
|
| Workload | 1 | 2011 | 168 | 0.080 |
Why?
|
| Altitude | 1 | 2014 | 462 | 0.070 |
Why?
|
| Social Class | 2 | 2009 | 264 | 0.070 |
Why?
|
| Motivation | 2 | 2012 | 600 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 5972 | 0.070 |
Why?
|
| Population | 1 | 2009 | 30 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1365 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2011 | 238 | 0.070 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 450 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 275 | 0.070 |
Why?
|
| Schools, Veterinary | 1 | 2008 | 3 | 0.070 |
Why?
|
| Specialty Boards | 1 | 2009 | 42 | 0.070 |
Why?
|
| Algorithms | 1 | 2017 | 1845 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2009 | 305 | 0.070 |
Why?
|
| Nutritional Status | 1 | 2011 | 353 | 0.070 |
Why?
|
| Professional Role | 1 | 2010 | 169 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2014 | 469 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2010 | 309 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 1043 | 0.070 |
Why?
|
| Nurses | 1 | 2010 | 171 | 0.070 |
Why?
|
| Disease Management | 2 | 2011 | 651 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2012 | 437 | 0.070 |
Why?
|
| Job Satisfaction | 1 | 2010 | 236 | 0.070 |
Why?
|
| Device Removal | 1 | 2009 | 142 | 0.070 |
Why?
|
| Mexican Americans | 1 | 2009 | 119 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2023 | 531 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 283 | 0.070 |
Why?
|
| Insulin | 2 | 2009 | 2510 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2008 | 167 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2014 | 834 | 0.060 |
Why?
|
| Mental Recall | 2 | 2021 | 217 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 360 | 0.060 |
Why?
|
| Morbidity | 1 | 2008 | 322 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2023 | 571 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 388 | 0.060 |
Why?
|
| Animals | 4 | 2019 | 37952 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2014 | 826 | 0.060 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2026 | 31 | 0.060 |
Why?
|
| RNA | 2 | 2023 | 910 | 0.060 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2026 | 33 | 0.060 |
Why?
|
| Triazines | 1 | 2026 | 49 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2008 | 216 | 0.060 |
Why?
|
| Indazoles | 1 | 2026 | 83 | 0.060 |
Why?
|
| Geography | 1 | 2006 | 185 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2026 | 67 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2026 | 316 | 0.060 |
Why?
|
| Anesthetics, Dissociative | 1 | 2025 | 46 | 0.060 |
Why?
|
| Utah | 1 | 2025 | 79 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 407 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 220 | 0.060 |
Why?
|
| Picolinic Acids | 1 | 2025 | 8 | 0.060 |
Why?
|
| Anesthetics, Intravenous | 1 | 2025 | 69 | 0.060 |
Why?
|
| Self Care | 1 | 2008 | 388 | 0.060 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 296 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1300 | 0.060 |
Why?
|
| Burn Units | 1 | 2025 | 41 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2006 | 327 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 451 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2025 | 70 | 0.050 |
Why?
|
| Calcium | 1 | 2011 | 1189 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2024 | 6 | 0.050 |
Why?
|
| Cannula | 1 | 2025 | 28 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 343 | 0.050 |
Why?
|
| Triazoles | 1 | 2026 | 187 | 0.050 |
Why?
|
| Germany | 1 | 2025 | 137 | 0.050 |
Why?
|
| Leukotriene Antagonists | 1 | 2024 | 24 | 0.050 |
Why?
|
| Pyridazines | 1 | 2024 | 57 | 0.050 |
Why?
|
| Missouri | 1 | 2004 | 66 | 0.050 |
Why?
|
| Feedback | 1 | 2025 | 180 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2024 | 18 | 0.050 |
Why?
|
| Lung | 1 | 2017 | 4101 | 0.050 |
Why?
|
| Sample Size | 1 | 2024 | 121 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2026 | 422 | 0.050 |
Why?
|
| Dyspnea | 1 | 2025 | 250 | 0.050 |
Why?
|
| Phentolamine | 1 | 2023 | 19 | 0.050 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2023 | 20 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2024 | 251 | 0.050 |
Why?
|
| Angiotensins | 1 | 2023 | 8 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 48 | 0.050 |
Why?
|
| Shock | 1 | 2024 | 109 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2024 | 129 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2022 | 1671 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2024 | 117 | 0.050 |
Why?
|
| Macrolides | 1 | 2003 | 67 | 0.050 |
Why?
|
| Calibration | 1 | 2023 | 151 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 608 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 19 | 0.050 |
Why?
|
| Remission Induction | 1 | 2023 | 306 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2008 | 775 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2023 | 98 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 39 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2024 | 224 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 229 | 0.050 |
Why?
|
| Emergency Medical Dispatch | 1 | 2022 | 4 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 273 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2022 | 46 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2023 | 396 | 0.040 |
Why?
|
| Information Systems | 1 | 2022 | 56 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2024 | 386 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 380 | 0.040 |
Why?
|
| Pulse Therapy, Drug | 1 | 2021 | 7 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2023 | 266 | 0.040 |
Why?
|
| Health Promotion | 2 | 2022 | 774 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 664 | 0.040 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 79 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 180 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2011 | 98 | 0.040 |
Why?
|
| Antimalarials | 1 | 2020 | 35 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2024 | 341 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 57 | 0.040 |
Why?
|
| Documentation | 1 | 2022 | 199 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 171 | 0.040 |
Why?
|
| Health Facilities | 1 | 2021 | 85 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 103 | 0.040 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 102 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2024 | 671 | 0.040 |
Why?
|
| HIV Infections | 2 | 2012 | 3186 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 5411 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 316 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 666 | 0.040 |
Why?
|
| Ergocalciferols | 1 | 2019 | 14 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2022 | 1579 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2003 | 943 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 979 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 562 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 361 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2024 | 955 | 0.030 |
Why?
|
| RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
|
| Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 1210 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 968 | 0.030 |
Why?
|
| Workflow | 1 | 2018 | 183 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 118 | 0.030 |
Why?
|
| Pregnancy | 1 | 2010 | 7182 | 0.030 |
Why?
|
| Historically Controlled Study | 1 | 2016 | 5 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 333 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 1134 | 0.030 |
Why?
|
| Ghana | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cell Communication | 1 | 2017 | 328 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2014 | 40 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 197 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 378 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2014 | 81 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2017 | 332 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1537 | 0.020 |
Why?
|
| Clinical Coding | 1 | 2013 | 27 | 0.020 |
Why?
|
| Internet | 1 | 2017 | 689 | 0.020 |
Why?
|
| Bed Occupancy | 1 | 2011 | 16 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 516 | 0.020 |
Why?
|
| Domestic Violence | 1 | 2011 | 51 | 0.020 |
Why?
|
| Salmeterol Xinafoate | 1 | 2010 | 20 | 0.020 |
Why?
|
| Pamphlets | 1 | 2010 | 26 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2010 | 52 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 216 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 282 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2010 | 49 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2949 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2012 | 410 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 731 | 0.020 |
Why?
|
| Research | 1 | 2011 | 430 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 708 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 236 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2010 | 260 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 844 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 3410 | 0.010 |
Why?
|